Linkin Website

Bio

Urvashi Prasad is a public policy specialist at NITI Aayog, the Indian Government’s premier think tank. She is also the founder of Every Voice, a platform that highlights the perspectives, needs, challenges and aspirations of people living in poverty in their own words. Urvashi was previously a Director at Operation ASHA, one of India’s largest tuberculosis control NGOs. She also led the health portfolio of the Michael & Susan Dell Foundation in India for five years. Urvashi is on the governing board of Partnership for TB Care & Control, the largest tuberculosis network in India. She completed her Bachelors in Genetics from University of Birmingham, UK, followed by a Masters in Bioscience Enterprise from University of Cambridge, UK and a Masters in Public Health from the London School of Hygiene & Tropical Medicine. Urvashi is passionate about gender-related and animal welfare issues. She is also a blogger and writes extensively for several platforms including the Huffington Post and Nextbillion.net.

Sessions

Linkin Website

Bio

Managing Director for boutique economic consulting firm EPG, specialising in economic analysis, strategic communications and market entry assistance with India, with offices in London, Bangalore and East Africa.

He was additionally, until August 2017, UK Director for the Federation of Indian Chambers of Commerce and Industry (FICCI), the premier and largest industry body in India. He is also the co-founder of a tech start-up in the CSR space. Previously he worked in Economic Consulting at FTI Consulting and Deloitte in London and Abu Dhabi, with a focus on public policy and arbitration. He was Chairman for a not-for-profit membership organisation with several thousand members for three years.

He studied Economics at Warwick University, where he was awarded the Prize for Excellence, and LMU University of Munich. His dissertation won a prize at an international economics conference at Georgetown University, Washington DC. He has published academic research on behavioural economics and social impact and is a regular commentator on public policy and India across print, TV and online media, featured on BBC News, CBC, CNBC, CNN, NDTV, South China Morning Post and Huffington Post.

Sessions

Website

Bio

Sessions

Linkin Website

Bio

Dr. James Wilkie is Director of Enterprise & Innovation for the University of Birmingham, CEO for Alta Innovations (the technology transfer company for the University of Birmingham), and CEO of the Birmingham Research Park, which houses two incubators including the BioHub Birmingham®, a fully equipped life sciences incubator.

Sessions

Facebook Linkin Twitter Website

Bio

After a 30-year stint as a professional editor and journalist that ended on April 30, 2016, Mr Narayanan Suresh formally joined ABLE on May 2, 2016 as its COO. The association was founded in 2003 to represent the interests of the fast-growing biotechnology industry.

For more than 13 years as the Editor of BioSpectrum, Mr N Suresh has worked closely with the biotech sector. Therefore, his rich experience and knowledge are expected to benefit the industry in due course of time. From being  a neutral observer to the biotech industry insider, his second innings now allows him to continue the association with sector.

The journalistic journey of Mr N Suresh began exactly 30 years ago in May 1996 when he joined the Times of India in New Delhi as their first-ever Exclusive Science Reporter, after a grueling 10-month training in Social Journalism with the Times Center for Media Studies( then called The Times Research Foundation School for Social Journalism) in the very first batch.

From a writer, in 1997 he moved to CyberMedia as the Associate Editor of DATAQUEST, the country’s leading IT publication, and it was a transformation, from being just a writer to an Editor-Manager. “The Chairman of Cybermedia, Mr Pradeep Gupta as well as one of its then Directors, Mr Shyam Malhotra believed in my capabilities and gave me many challenging roles that involved creating strong publication brands, says Suresh nostalgically.

At CyberMedia, he was later involved in launching and building the BioSpectrum magazine, the only source of information for biotech industry back then. Later, he also moved on with the brand to MM Activ Sci-Tech Communications when it was acquired by the later. During his long stint as the Editor, he managed and edited various publications within these publishing houses.

Sessions

Twitter Website

Bio

Andy Street, CBE (born 11 June 1963), is a British businessman and politician who was the managing director of John Lewis from 2007 to 2016. He is now the Conservative Mayor of the West Midlands, elected in the May 2017 mayoral election. As such, he is the United Kingdom’s first openly gay directly-elected metro mayor.

Sessions

Linkin Website

Bio

Tony Hickson BSc, MBA, CLP, RTTP is Managing Director of Imperial Innovations and an Executive Director on the board of Touchstone Innovations plc. Tony is responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Prior to joining the company in 2002, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group, Murex Biotech, Abbott Laboratories and Kalibrant Limited.

He has been a board director or observer for a number of start-up companies including Emcision, Polytherics (now Abzena) and Catapult Therapy TCR Limited, and was instrumental in the creation of companies such as Thiakis (sold to Wyeth, now Pfizer, in 2008), Respivert (sold to J&J in 2010), Circassia (floated on LSE in 2014) and Cell Medica (in advanced clinical studies). Tony is a Certified Licensing Professional, a board director of PraxisUnico and until recently acted as Chairman of the Intellectual Property Board of the European Institute of Technology Climate Change KIC.

Sessions

Website

Bio

Lars Dahle is the Founder, and has been CEO of Digno since its inception in 2012. He is a thought-leader in the use of Telehealth and Remote Patient Monitoring in Norway and is an advisor to health care policymakers in the parliament of Norway. Government agencies and LocaL Mnicipal bodies. His focus is on understanding and overcoming the organisational inhibitors of telecare providers to start and then scale up the use of Telehealth/Remote Patient Monitoring.

Before Dignio, Mr Dahle held senior management positions in Telecom operators and IT-vendors, such as HP. He holds a MS in Computer Science from the Technical University of Norway  (NTNU) and a MS in Management from MIT, Solan School of Management.

Sessions

Linkin Twitter Google+ Website

Bio

Ms. Anu Acharya is the CEO of Mapmygenome India, a Genomics company whose vision is “To touch 100 million lives”. In 2013, she introduced the concept of improved healthcare through personal genomics in India. Ever since, she has successfully pioneered the company through growing product lines, expanding affiliate network and has received funding from stalwarts like Mr. Ratan Tata and Mr. Rajan Anandan and more. She is a distinguished alumna from IIT Kharagpur.

Under her able leadership, the company has won several awards and honors: ET Startup Awards 2015 – Women Ahead, Nasscom Emerge 50 – League of 10, Emerging Company of the Year 2015 – Govt. of Karnataka, SMART CEO List of Top 50 Startups, VCCircle Innovative Healthcare Startup 2015, Wall Street Journal’s top global startups 2016, Red Herring Asia and Global 2016, and more.

From 2000 until April 2013, Ms. Anu Acharya was the CEO of Ocimum Biosolutions, a global genomics outsourcing partner for discovery, development and diagnostics, a company that began as a pure Bioinformatics company. Since co-founding the company in 2000, she has led the company through three strategic international acquisitions, two capital raises for equity investments and launch of several innovative products, solutions and services through its proprietary platform called RaaS (Research as a Service). An author of several research papers published in major journals, various articles for journals like Nature, Ms. Anu Acharya recently received early publication approval for her patent for SNaPpy –  the genetic risk prediction algorithm developed in-house at Mapmygenome. She has been invited to various institutions globally (academia as well as commercial) to share her knowledge, expertise and experience in the fields of genomics and entrepreneurship.

Books authored: (list not exhaustive)

1. Software Innovations in Clinical Drug Development and Safety (link)
2. Pharmaceutical Outsourcing: Discovery and Preclinical Services (Pharmaceutical Outsourcing, Volume I) (link)
3. Healthcare ethics and training: Chapter on Impact of human exome sequencing on clinical research (link)
4. Atomic Pohe

Books in which Ocimum/Mapmygenome is covered: (List not exhaustive)

1. From Campus to Corporate
2. The Game Changers
3. Biomedical Innovation in India: Comparison to China
4. Women Entrepreneurs: Inspiring Stories from Emerging Economies
5. Emerging Markets Rule: Growth Strategies of the New Global Giants

Case Studies on Ocimum/Mapmygenome

1. Harvard Business : https://hbr.org/product/ocimum-biosolutions-from-bioinformatics-to-integra/an/W11198-PDF-ENG

Boards

She currently serves as a Governing Board member at the NIBMG (National Institute for Biomedical Genomics). She is on the Board of Mentors for IvyCap Ventures and Advisory Board at Flag A Spot, Action for India & KIIT. She is also a member of CII National Committee on Biotechnology 2016-2017.

Ms. Acharya had served in the past as a Governing Board member at CSIR (Council for Scientific and Industrial Research), the Vice Chair of the Global Agenda Council on Genetics for the World Economic Forum, on the board of ABLE (Association of Biotech Led Enterprises), and as President of the Hyderabad chapter of the Entrepreneurs’ Organization.

Awards & Honors

In May 2016, Women Economic Forum honored Mapmygenome her with the award Iconic Innovative Trailblazers of the Decade. In 2015, she won the Women Ahead category and made it to the top 5 innovators list in the Economic Times Startup Awards. In October 2015, Anu Acharya received the FICCI FLO Women Achiever’s Award in the category Innovation through Technology. She was named a Young Global Leader by the World Economic Forum for its class of 2011.  The British High Commission also named her part of the “Young Leaders Forum” in 2013.

She was selected by Red Herring Magazine to the list of 25 Tech Titans under 35 in 2006. She was named Biospectrum Entrepreneur of the Year for 2008 and received the Astia Life Science Innovators Award in the same year.

Past Positions & Education

Prior to founding Ocimum Biosolutions, Ms. Acharya has had rich experience in the Telecom, IT and entrepreneurship arenas. She worked for a start-up in the telecommunications space called Mantiss Information and a consulting firm called SEI Information where she helped create a social networking site for entrepreneurs. Her experience is backed by education at premier institutions such as the Indian Institute of Technology at Kharagpur, India (IIT) and University of Illinois where she has two Postgraduate degrees in Physics and MIS.

Sessions

Linkin Website

Bio

Sessions

Linkin

Bio

Sessions

Linkin e-mail Website

Bio

The Managing Director of Clonz, Narasimha is one of the key founding members of the company. His passion and vision combined with his academic and industrial experience in the world of Proteins (Proteomics) is the driving force of the company towards developing affordable bio therapeutics.

Narasimha’s Research experience in Cancer Biology at CCMB (Centre for Cellular and Molecular Biology) helped him to contribute through his work at a USA based MNC as Product Manager for its Indian subsidiary and  also as a Group Leader – Proteomics & Genomics for a reputed CRO, prior to the birth of Clonz.

His wide exposure to countries like Malaysia, Korea, Thailand, China, France, Germany, Switzerland, and USA on various business assignments is also helping in positioning the company.

Sessions

Linkin Website

Bio

Salman Rahman has a career in biomedical research spanning over 25 years working at some of the UK’s leading academic and biomedical research institutions. Salman began his research career studying the biochemistry of gap junctions at the National Institute for Medical Research (MRC) using targeted antibody technology to elucidate the structure-function of connexins leading to his PhD in 1991. Following post-doctoral posts at the Thrombosis Research Institute London and at the Centre for Thrombosis and Haemostasis at St Thomas’ Hospital, where he studied the structure-function of disintegrins, Dr Rahman was appointed as Lecturer at King’s College London between 1999-2009 where he investigated the role of the extracellular matrix and disintegrin-metalloproteinase (ADAMs) in regulating vascular cell signalling in the context of angiogenesis and cardiovascular disease. His research with colleagues during this period led to discoveries that would underpin the development of Vasgen.

Dr Rahman has published over 30 papers with esteemed colleagues from the UK, US and China and holds an Honorary Senior Lectureship in the Dept. Cell Biology at the UCL Institute of Ophthalmology. In 2011, he co-founded Vasgen, where he is currently the CEO, in order to develop novel therapeutic technologies.

Sessions

e-mail Website

Bio

Sessions

Website

Bio

Dr. Vijay Agarwal is a Senior Consultant Medical Oncologist with over 12 years of experience in Oncology. Prior to joining HCG he was working as a Consultant in Medical Oncology at Queen Elizabeth Hospital, Birmingham, UK.

Having completed his training in Medicine (MD) at Manipal Academy of Higher Education, he travelled to England to specialise in Medical Oncology and worked in various prestigious institutes such as the Royal Marsden Hospital, London; Kings College Hospital, London, Leeds teaching Hospital, Leeds and Queens Centre for Oncology, Hull, and completed his MRCP and Specialist training in oncology (CCT).

 Due to his keen interest in Medical research, he took some time out and devoted himself to cancer research which led to the award of a PhD by Hull York Medical School, UK. He has authored various papers that have been published in peer reviewed international journals and he has presented at conferences around the world.

He specialises in delivering chemotherapy and targeted therapy in solid tumours and strongly believes in practising evidence based medicine with patient centred approach. He keeps himself abreast with the latest developments in Oncology and aspires to deliver the best possible treatment and care to all his patients.

Sessions

Website

Bio

Andrew has responsibility for ensuring that processes are aligned and optimised to support the introduction and uptake of technologies and best practices. This entails creating an on going dialogue between industry and policy makers to ensure efficient and effective access and payment structures are created and maintained.

In addition to the Market Access portfolio Andrew also leads on the ABHI Ethics and Compliance program. This includes credentialing, Code of Business Practice and Human Rights.

Having graduated with a degree in Applied Physics, Andrew entered the commercial environment and has gained over 20 years experience in the medical devices industry having worked within medical technology divisions of household names such as Thorn EMI, Philips and Bristol-Myers Squibb. He has held roles covering UK and international marketing, market access and business development working with both capital and consumable equipment.

Sessions

Linkin Website

Bio

Anthony Finbow has achieved success over many years as a CEO of technology businesses. Having occupied every seat at the board table: Chairman, CEO, CFO, NXD and Investor Director (for both public and private companies), he is uniquely qualified to assist Leaders and their management teams in meeting and overcoming the most significant challenges that they will encounter on their journey.

He helps Leaders across Europe by providing enlightened and creative coaching support and advice. In addition to coaching services, he provides Leadership education, training and strategy consulting services to independent businesses in the “scale up” phase, to large corporations engaged in significant change and to government.

Sessions

Linkin Website

Bio

Sessions

Website

Bio

Jon has 30 years experience working in the life sciences, during which he has undertaken a wide range of roles in industry and academia. These included co-founding CTM BioTech, which offered a range of contract services from early-stage process development and pre-clinical produc – tion to later-stage project management, and working for several years as a life sciences management consultant.

Jon holds a BSc in Microbiology with Genetics and an MSc in Medical Microbiology from the University of London, and an MBA from the Open University. He is a Fellow of the Institute of Medical Laboratory Sciences in Bacteriology.

Sessions

Website

Bio

Fiona is an entrepreneurial Chief Executive who has successfully established and grown biotechnology businesses. She has led Absynth Biologics since 2008 to advance the Company’s technology platform and pipeline; comprising vaccines to prevent bacterial infections caused by S. aureus and C. difficile. Previously Fiona co-founded the anti-infectives company Novacta Biosystems and was Chief Executive until late 2007. In her early business career Fiona founded and managed Healthcare Ventures Limited, a European incubator company, for the Rothschild Bioscience Unit and J&J Development Corporation. Her broader interests are in supporting entrepreneurs with early stage businesses, working on expert panels with BBSRC, the Royal Society of Edinburgh, Biotechnology Young Entrepreneurs’ Scheme and the Stevenage Bioscience Catalyst. A 2017 finalist in the InFocus Women in Innovation’s awards, Fiona has a PhD in Biochemistry (Kent) and an MBA from London Business School.

Sessions

Website

Bio

Hitesh Thakrar is a Partner of Syncona Investment Management Ltd. He is an experienced investor in the sector, having spent over 20 years investing in public global equities in the life sciences, technology and the innovation sectors.

He has worked at various institutions in equity research and Fund Management from ADIA, the sovereign wealth Fund of Abu Dhabi, JP Morgan, Aviva Group, Dresdner Bank and New Star Asset Management. He has a strong track record, rated AA manager and was also a top 1 percentile manager in global equities. He is on the Board of Desktop Genetics, a CRISPR IP library company, backed by Illumina and is an angel investor in early stage Innovation companies. He is also on the Investment Committee of the LBA Scale Up Innovation Fund.

Hitesh holds a degree in Chemistry from Kings College, London, MBA from Cranfield University and CFA, the American Association of Investment Analysts.

Sessions

Linkin Website

Bio

In charge of Quantumzyme’s science and strategy, Naveen comes with over 20 years of scientific & entrepreneurial experience in the drug discovery industry across the USA, Australia and India.

He has published several research papers and the most notable was published in Nature in July 2017 with a few more interesting discoveries in the pipeline for the year.

Naveen is an entrepreneur and hands-on executive officer with extensive knowledge of Pharma, Healthcare, regulatory and medical devices scenario in India. Solid Healthcare, Life Sciences background known for strategic and focused approach, with extensive accolades for establishing creative strategies for optimizing internal operations, financial returns, limiting risk, creating lean teams, and external customer service and output.

Prior to founding Quantumzyme, he served as the CEO of Cryo Stemcell and prior to that as Director at Philips Research, where he was associated with a portfolio of opportunities for new business creation in healthcare and energy. In his previous roles, he has risen through the ranks – from being a bench worker at an Australian research institute to heading the strategic business unit of an American drug discovery informatics company. He has conceptualized and developed novel solutions for accelerating drug discovery and directed teams consisting of experts from different domains including chemistry, proteomics and systems biology. He has been instrumental in conceiving new ideas that are the basis for the company’s patent portfolio.

Has been a speaker and presenter in several international conferences.

• World Congress for Preventive and Regenerative Medicine, Taiwan.
• ABLE Bioinvest
• Bangalore Bio
• Bio Partnering Europe, London, UK.
• Bio North America, Vancouver, Canada.
• Beyond Genome Conference, San Diego, USA.
• IBM High Performance Computing conference, Hyderabad, India

Guest Lectures in several institutions like:

• IIT Madras
• University of Virginia
• University of California, San Diego
• Indian Business Academy, Bangalore, INDIA

Advisor – Board of Studies at:

• Welingkar Institute of Management
• Department of Biotechnology, SDM Group of Institutions

Previous engagements:

CEO – Cryo Stemcell

Overview of the profile:

Turnaround of the company from a Stem cell banking service provider to become a healthcare company and developed the roadmap and business plan for next level funding. Initiated PRP therapy and Hospital partnerships with new customer acquisition and sales team mobilization pan India.

Director – Philips Research Asia

Overview of the profile:

As Director Business Development at Philips Research Asia, Naveen was involved in identifying and developing technology ventures for spin-ups, spin-ins (technology acquisition) and spin-outs in Philips. He has successfully developed and managed a portfolio of opportunities for New Business Creation across Healthcare and Energy relevant for India, emerging markets and globally.

CEO – Polyclone Bioservices

Overview of the profile:

Founded Polyclone and lead the company as a CEO and successfully forged Drug Discovery Alliances, developed markets for Genomics and Proteomics services, Virtual Screening and Research Information Systems.

• Responsible for developing a Govt. recognized R&D unit
•  Successfully raised R&D Grants from various national and international agencies
•  Managing research projects from start to finish in various areas of cancer genomics
•  Filing of the first patent for a cancer target

Principal Consultant, Life Science – SysArris Inc, USA

Overview of the profile:

Initiated and implemented Bioinformatics services for SysArris. Established niche offerings and positioned the company as a leading provider of consulting, technology, outsourcing and applied research services for pharma and biotech industry.

RESEARCH

CRC for Diagnostics Technologies (CDT) Brisbane, Australia Summary:

CDT is an A$40 million/yr. Co operative research center and a consortium of academic partners and members of Australian Diagnostics Manufacturers Association, sited at Brisbane. This Project involved developing a novel Polymerase Chain Reaction (PCR) based DNA diagnostic assay, utilizing the Amplification Refractory Mutation System (ARMS) principle for the detection of single gene mutations.

EDUCATION

MSc, Applied Science (Life Science) Queensland University of Technology, Brisbane, AUSTRALIA BSc, Microbiology, Bangalore University, INDIA

Sessions

Linkin Twitter Website

Bio

Phillip D’Costa is an experienced Partner specialising in commercial, fraud, IT and financial services dispute resolution, arbitration and ADR. Phillip has been ranked as a leading individual for UK and India dispute resolution in Chambers Global 2014 and foreign expert in Chambers Global 2015.

Key areas of practice:
• Commercial – Litigation & Arbitration, jurisdictional issues, partnership/LLP, contractual claims, shareholders, Technology, director’s duties and insolvency;
• Civil Fraud – Company investigations, restitution claims, misrepresentation, asset tracing, freezing & recovery, supply chain fraud, employee fraud;
• Financial Services & Regulatory – Securitisation, asset finance, leasing, share fraud, miss-selling, derivatives and structured products, money laundering, regulatory, compliance;• Has a particular interest in arbitration and transactional work involving India and has advised on a number of disputes and transactions involving India or Indian Companies, Families and Individuals.

Specialities:
Civil Fraud – Company investigations, Freezing Orders, Fraud investigation and Asset tracing.

Commercial – Litigation & International arbitration, jurisdictional issues, partnership and LLP advice and disputes, IT & IP disputes, contractual claims, shareholders disputes, Asset Finance & Leasing, Cross border transactions, Insolvency and Licensing.

Financial Services & Regulatory – miss-selling, money laundering, regulatory, compliance.

Sessions

Website

Bio

Andrew Fried is IBM Life Sciences Leader for Europe.

Andrew helps clients address industry imperatives and save lives through the power of cognitive insights.  He works with clients to advance the next generation of discovery and development, acting on insights to drive value, enhance relationships across the ecosystem and empowering people to make better decisions.

Prior to transferring to Europe in July 2015, Andrew was IBM’s Life Sciences Leader for China. While in China Andrew worked with many leading multi-national companies and several Chinese Life Sciences companies who were leaders in their respective segment.

Before joining IBM in 2000, Andrew had a successful 14-year career with a leading strategy consulting company.  He graduated from Melbourne University with a Bachelor of Arts, and Monash University (Melbourne, Australia) with a Bachelor of Business.  Andrew has a Masters of Business Administration from the International University of Japan and is a Fellow of the Financial Services Institute of Australasia. He was a three-term board member on a government enterprise with assets of over $350M. He was a founding director of a successful dot.com start-up in the early 2000s.

Andrew is an advocate of sport and fitness as a gateway to good health.  He is passionate about the role of genomics in identifying both the cause of disease and personalized solutions.

Sessions

Website

Bio

Dr. Aman Puri assumed charge as Consul General of India, Birmingham on 22 February, 2017. He is a member of the Indian Foreign Service, having joined the service in 2003. He served at the Indian Mission to the European Union, Belgium and Luxembourg, based at Brussels, from 2005-08. He served at the Passport Office in Chandigarh for little over a year from 2009-10.

Subsequently, he held the office of Deputy Chief of the Protocol (Ceremonial) from 2010-2013, and his responsibilities included organising the foreign visits of Prime Minister of India, and the incoming visits at the level of Heads of States/Heads of Government, Vice Presidents and Foreign Ministers.

Dr. Puri was the Regional Passport Officer, New Delhi from 2013-16, during which period many citizen centric measures were implemented by the Ministry of External Affairs.

Most recently, he had brief stints as Director in the Multi-lateral Economic Relations Division, followed by the Northern Division of the Ministry of External Affairs. The Northern Division deals with India’s relations with Nepal and Bhutan.

Dr. Puri (born 1976) did his schooling from St. John’s High School, Chandigarh, and qualified as Dentist from Dental College based at Amritsar.

Sessions

Website

Bio

Dr. Vishwas is a molecular virologist with over 18 yrs experience in bio/pharmaceutical discovery research at leading Indian pharmaceutical companies. He was associated with the discovery & pre-clinical development of 2 NCEs and also helped establish the protein therapeutics research center of Glenmark Pharmaceuticals at Neuchatel, Switzerland. Dr. Vishwas has concieved & developed the eSAME technology platform of Seagull BioSolutions.

Sessions

Linkin e-mail Website

Bio

Chris is a partner in the Oxford office who specialises in intellectual property and commercial law, and EU and UK competition laws. He trained at a multinational law firm, qualifying into the commercial department in 1986. He joined the firm in 1990 and became a partner in 1992. Chris is particularly known for his work in the life sciences, publishing and engineering sectors, and for universities, research councils and their spin-out companies.

One of only ten UK lawyers who are highly recommended for patent licensing in IAM 1000: The World’s Leading Patent Practitioners, Chris is described as ‘extremely strong’ and as having ‘an assured command of the life sciences, publishing and engineering sectors’. He is also a Chambers UK leading expert and is rated in band 1 for intellectual property by both Chambers UK and The Legal 500. Client quotes in Chambers UK 2017 describe Chris as having ‘a brilliant grasp of commercial IP matters’.

Chris chairs the life sciences stream of the new IP Transactions: Law and Practice course run by the UCL Institute of Brand & Innovation Law, for which he delivers the patent licensing seminar. This course was highly commended in the Law Society Excellence Awards 2013.

Sessions

Website

Bio

Sabeena Kalla is the Scientific & Evaluation Director of Eurasanté.
For more than 10 years, she has been actively involved in the creation of more than 50 companies (SME) based on cutting edge technologies from regional laboratories & companies involved in the healthcare and nutrition sector. She helps regional and European entrepreneurs to develop and bring to market innovative products, services and processes which have a strong environmental value and can be replicated and multiplied across the EU and at an international level.

Mrs Kalla began her career in 1992 at the LFB, an international player in the plasma-derived medicinal products area, with recognized expertise in plasma fractionation. She has been developing numerous projects relative to purification of Immunoglobulins from plasma fractionation.

She is a postgraduate in Cellular and Molecular Engineering, in Macromolecular Chemistry and has a Master of Business Administration. She led research Programs at the Pasteur Institute of Lille (peptide synthesis) and at the LFB (Immunoglobulins).

Sessions